An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms CheckMate870
- Sponsors Bristol-Myers Squibb
- 03 Oct 2017 Planned initiation date changed from 30 Sep 2017 to 26 Oct 2017.
- 11 Jul 2017 Planned End Date changed from 30 Jul 2022 to 30 Jul 2020.
- 27 Jun 2017 New trial record